Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
gut microbiota1104 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A44026 | 30116145 | Mediators Inflamm | Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease". | 2018 | Details |
| A44065 | 29993258 | Crit Rev Food Sci Nutr | The target cells of anthocyanins in metabolic syndrome. | 2018 | Details |
| A44118 | 29694888 | Cell Rep | Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. | 2018 | Details |
| A44176 | 29507905 | Hepatol Commun | Pyrroloquinoline quinone prevents developmental programming of microbial dysbiosis and macrophage polarization to attenuate liver fibrosis in offspring of obese mice. | 2018 | Details |
| A44225 | 29327584 | J Agric Food Chem | Gamma-aminobutyric Acid Enriched Rice Bran Diet Attenuates Insulin Resistance and Balances Energy Expenditure via Modification of Gut Microbiota and Short-Chain Fatty Acids. | 2018 | Details |
| A44308 | 29075166 | EXCLI J | Retraction: Nonalcoholic fatty liver disease, diet and gut microbiota. | 2017 | Details |
| A44337 | 28936971 | Turk J Gastroenterol | Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. | 2017 | Details |
| A44389 | 28736228 | Biochim Biophys Acta Gen Subj | DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis. | 2017 | Details |
| A44458 | 31089501 | J Obes Metab Syndr | The Roles of the Gut Microbiota and Toll-like Receptors in Obesity and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A44646 | 27822554 | mSystems | Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism. | 2016 | Details |
| A44744 | 27477080 | Transl Res | Gut microbiome and liver disease. | 2016 | Details |
| A44808 | 27252163 | Physiology (Bethesda) | Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. | 2016 | Details |
| A44859 | 27048892 | Best Pract Res Clin Gastroenterol | Dysbiosis in gastrointestinal disorders. | 2016 | Details |
| A44883 | 26984853 | Gut | Gut microbiota produce alcohol and contribute to NAFLD. | 2016 | Details |
| A44943 | 26655287 | Curr Opin Lipidol | Choline metabolites: gene by diet interactions. | 2016 | Details |
| A44972 | 26571774 | Nihon Naika Gakkai Zasshi | [Gut Microbiota and Internal Diseases: Update Information. Topics: III. NASH/NAFLD and gut microbiota]. | 2015 | Details |
| A44980 | 26537323 | Nihon Shokakibyo Gakkai Zasshi | [Gut microbiota and NASH]. | 2015 | Details |
| A45098 | 26087059 | Clin Transl Gastroenterol | The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. | 2015 | Details |
| A45145 | 25922396 | Clin Infect Dis | New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. | 2015 | Details |
| A45217 | 28210672 | Cell Mol Gastroenterol Hepatol | The Gut Microbiota, Intestinal Permeability, Bacterial Translocation, and Nonalcoholic Fatty Liver Disease: What Comes First? | 2015 | Details |
| A45219 | 25625278 | PLoS Pathog | Implication of gut microbiota in nonalcoholic fatty liver disease. | 2015 | Details |
| A45353 | 25073467 | Pharmacol Rev | Bile acid signaling in metabolic disease and drug therapy. | 2014 | Details |
| A45391 | 24849166 | Aliment Pharmacol Ther | Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply. | 2014 | Details |
| A45392 | 24849165 | Aliment Pharmacol Ther | Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease. | 2014 | Details |
| A45434 | 24629562 | Metabolism | Obesity-associated mechanisms of hepatocarcinogenesis. | 2014 | Details |
| A45444 | 24516926 | Zhonghua Gan Zang Bing Za Zhi | [Current status of gut microbiota and metagenome with nonalcoholic fatty liver disease]. | 2013 | Details |
| A45508 | 24217034 | Ann Nutr Metab | Clinical consequences of diet-induced dysbiosis. | 2013 | Details |
| A45571 | 23840101 | Mediators Inflamm | Influence of gut microbiota on subclinical inflammation and insulin resistance. | 2013 | Details |
| A45718 | 23112961 | Front Cell Infect Microbiol | Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. | 2012 | Details |
| A45912 | 22122483 | Curr Pharm Biotechnol | Intestinal MicrobiOMICS to define health and disease in human and mice. | 2012 | Details |
| A45965 | 21807932 | JPEN J Parenter Enteral Nutr | Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. | 2011 | Details |
| A46367 | 19271298 | J Pediatr Gastroenterol Nutr | Intestinal microbiota during infancy and its implications for obesity. | 2009 | Details |
| A46903 | 35053298 | Cells | NLRP6 Inflammasome Modulates Disease Progression in a Chronic-Plus-Binge Mouse Model of Alcoholic Liver Disease. | 2022 | Details |
| A46931 | 33816353 | Front Cell Infect Microbiol | Streptococcus, the Predominant Bacterium to Predict the Severity of Liver Injury in Alcoholic Liver Disease. | 2021 | Details |
| A46956 | 32583604 | Mol Nutr Food Res | Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. | 2020 | Details |
| A46969 | 31955762 | Food Res Int | Alteration of gut microbiota composition by short-term low-dose alcohol intake is restored by fermented rice liquor in mice. | 2019 | Details |
| A46996 | 30857422 | FASEB J | Solid-state fermented Chinese alcoholic beverage (baijiu) and ethanol resulted in distinct metabolic and microbiome responses. | 2019 | Details |
| A47004 | 30643227 | Nat Rev Gastroenterol Hepatol | Alcohol, liver disease and the gut microbiota. | 2019 | Details |
| A47012 | 30105955 | Exp Biol Med (Maywood) | Mulberry and dandelion water extracts prevent alcohol-induced steatosis with alleviating gut microbiome dysbiosis. | 2018 | Details |
| A47044 | 28228158 | Lipids Health Dis | Flaxseed oil ameliorates alcoholic liver disease via anti-inflammation and modulating gut microbiota in mice. | 2017 | Details |
| A47076 | 26751488 | Biomolecules | Alcoholic Liver Disease: Update on the Role of Dietary Fat. | 2016 | Details |
| A47199 | 23206305 | Zhonghua Gan Zang Bing Za Zhi | [Changes in the intestinal microenvironment during development of alcoholic fatty liver disease and related effects of probiotic therapy]. | 2012 | Details |
| A47273 | 19645728 | Alcohol Clin Exp Res | Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. | 2009 | Details |
| A47710 | 33163830 | Hepatol Commun | Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. | 2020 | Details |
| A47750 | 32555455 | Nature | A metabolic pathway for bile acid dehydroxylation by the gut microbiome. | 2020 | Details |
| A47785 | 31973190 | Nutrients | Current Knowledge about the Effect of Nutritional Status, Supplemented Nutrition Diet, and Gut Microbiota on Hepatic Ischemia-Reperfusion and Regeneration in Liver Surgery. | 2020 | Details |
| A47893 | 29907951 | Anal Bioanal Chem | Analysis of human C24 bile acids metabolome in serum and urine based on enzyme digestion of conjugated bile acids and LC-MS determination of unconjugated bile acids. | 2018 | Details |
| A48563 | 34066850 | Microorganisms | Human Gut Microbiome and Liver Diseases: From Correlation to Causation. | 2021 | Details |
| A48594 | 33426525 | Brain Commun | Diet-dependent gut microbiota impacts on adult neurogenesis through mitochondrial stress modulation. | 2020 | Details |
| A48643 | 32564086 | Int Immunol | The impact of metabolites derived from the gut microbiota on immune regulation and diseases. | 2020 | Details |
| A48691 | 31405111 | Medicina (Kaunas) | Targeting Microbiota: What Do We Know about It at Present? | 2019 | Details |
| A48728 | 30483228 | Front Microbiol | Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function. | 2018 | Details |
| A48737 | 30279623 | J Clin Biochem Nutr | Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. | 2018 | Details |
| A48750 | 29774155 | United European Gastroenterol J | Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased? | 2017 | Details |
| A48785 | 28770495 | Curr Infect Dis Rep | Fecal Microbiota Transplantation: Beyond Clostridium difficile. | 2017 | Details |
| A48789 | 28711599 | Biochim Biophys Acta Mol Basis Dis | Arachidonic acid sex-dependently affects obesity through linking gut microbiota-driven inflammation to hypothalamus-adipose-liver axis. | 2017 | Details |
| A48940 | 23768554 | Best Pract Res Clin Gastroenterol | Diabetes, obesity and gut microbiota. | 2013 | Details |
| A48996 | 21995448 | Microb Cell Fact | Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. | 2011 | Details |
| A49221 | 35817360 | Pharmacol Res | Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. | 2022 | Details |
| A49234 | 35813333 | Ann Transl Med | Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice. | 2022 | Details |
| A49262 | 35806934 | J Clin Med | The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. | 2022 | Details |
| A49300 | 35795340 | Nanotheranostics | Emerging Role of Edible Exosomes-Like Nanoparticles (ELNs) as Hepatoprotective Agents. | 2022 | Details |
| A49301 | 35795290 | Evid Based Complement Alternat Med | Cannabis Extract Effects on Metabolic Parameters and Gut Microbiota Composition in a Mice Model of NAFLD and Obesity. | 2022 | Details |
| A49308 | 35792869 | FASEB J | Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis. | 2022 | Details |
| A49335 | 35784718 | Front Pharmacol | Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice. | 2022 | Details |
| A49338 | 35784533 | Front Endocrinol (Lausanne) | Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A49364 | 35777915 | J Adv Res | Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug. | 2021 | Details |
| A49374 | 35770155 | Front Microbiol | Gut Microbial Profile in Asymptomatic Gallstones. | 2022 | Details |
| A49405 | 35761655 | Food Res Int | Pueraria lobata starch regulates gut microbiota and alleviates high-fat high-cholesterol diet induced non-alcoholic fatty liver disease in mice. | 2022 | Details |
| A49415 | 35758365 | Medicine (Baltimore) | CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients. | 2022 | Details |
| A49429 | 35752255 | J Control Release | Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis. | 2022 | Details |
| A49478 | 35740464 | Biomedicines | The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. | 2022 | Details |
| A49497 | 35736447 | Metabolites | Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. | 2022 | Details |
| A49524 | 35726797 | Food Funct | Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. | 2022 | Details |
| A49530 | 35724509 | Biomed Pharmacother | Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. | 2022 | Details |
| A49541 | 35721143 | Front Pharmacol | Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. | 2022 | Details |
| A49595 | 35697165 | Int J Biol Macromol | Extraction, purification, structural characterization, and gut microbiota relationship of polysaccharides: A review. | 2022 | Details |
| A49601 | 35694542 | Front Cell Infect Microbiol | The Microbiota and It's Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49614 | 35691078 | Phytomedicine | The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis. | 2022 | Details |
| A49640 | 35682957 | Int J Mol Sci | Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis. | 2022 | Details |
| A49646 | 35681289 | Foods | Non-Alcoholic Components in Huangjiu as Potential Factors Regulating the Intestinal Barrier and Gut Microbiota in Mouse Model of Alcoholic Liver Injury. | 2022 | Details |
| A49665 | 35677177 | Comput Math Methods Med | Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49670 | 35675435 | Sci Transl Med | Risk assessment with gut microbiome and metabolite markers in NAFLD development. | 2022 | Details |
| A49694 | 35667460 | Int J Biol Macromol | Chondroitin sulfate stimulates the secretion of H2S by Desulfovibrio to improve insulin sensitivity in NAFLD mice. | 2022 | Details |
| A49707 | 35663007 | World J Clin Pediatr | Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. | 2022 | Details |
| A49708 | 35662935 | Front Nutr | Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis. | 2022 | Details |
| A49732 | 35655096 | Acta Pharmacol Sin | Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. | 2022 | Details |
| A49746 | 35651514 | Front Nutr | Polydatin, A Glycoside of Resveratrol, Is Better Than Resveratrol in Alleviating Non-alcoholic Fatty Liver Disease in Mice Fed a High-Fructose Diet. | 2022 | Details |
| A49752 | 35647690 | Microbiol Spectr | Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. | 2022 | Details |
| A49759 | 35646144 | Evid Based Complement Alternat Med | Inhibitory Effects of Mongolian Medicine Yihe-Tang on Continuous Darkness Induced Liver Steatosis in Zebrafish. | 2022 | Details |
| A49762 | 35644678 | J Cannabis Res | THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet. | 2022 | Details |
| A49770 | 35643287 | J Nutr Biochem | Opisthorchis viverrini infection induces metabolic disturbances in hamsters fed with high fat/high fructose diets: Implications for liver and kidney pathologies. | 2022 | Details |
| A49802 | 35633911 | World J Gastroenterol | Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. | 2022 | Details |
| A49809 | 35630624 | Molecules | Hepatoprotective Effects of Ixeris chinensis on Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice: An Integrated Gut Microbiota and Metabolomic Analysis. | 2022 | Details |
| A49843 | 35624084 | J Gastroenterol Hepatol | Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49861 | 35616069 | Food Funct | Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis. | 2022 | Details |
| A49913 | 35598686 | Gene | Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A49925 | 35592528 | Oxid Med Cell Longev | Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. | 2022 | Details |
| A49953 | 35584453 | Braz J Med Biol Res | The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. | 2022 | Details |
| A49954 | 35583582 | Chin J Integr Med | Molecular Mechanism of Polysaccharides Extracted from Chinese Medicine Targeting Gut Microbiota for Promoting Health. | 2022 | Details |